Jazz Pharmaceuticals’ chemotherapy Vyxeos has won the backing of the National Institute for Health and Care Excellence (NICE) for routine use on the NHS in England and Wales to treat certain acute myeloid leukaemias (AML).
Original Article: NICE nod for Jazz’ AML chemo